Saturday, January 01, 2011 1:23:02 PM
All good points and in time stock prices will reflect true value -- just not at all times. When true value is not reflected, opportunity presents itself to either go long or short. When I take into consideration the market cap and compare it with other small bios, well, OU, all I see is an amazing opportunity.
The technicals concern me too. CYCC has been in a channel for about 6 months and it seems we are testing lower support these days. This needs to hold but, without a catalyst, I'm afraid TA traders might not have enough ammo to support current prices.
I remain bullish and believe your target of $3 is reasonable.
The technicals concern me too. CYCC has been in a channel for about 6 months and it seems we are testing lower support these days. This needs to hold but, without a catalyst, I'm afraid TA traders might not have enough ammo to support current prices.
I remain bullish and believe your target of $3 is reasonable.
I am not a very smart man. If you trade based solely on my opinion, which changes at the drop of a hat, you are a moron! I am an emotional and irrational wreck!
Recent CYCC News
- Bio Green Med Solution, Inc. Announces Closing of Strategic Acquisition of Fitters Sdn. Bhd. • GlobeNewswire Inc. • 09/12/2025 10:00:00 AM
- Cyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/13/2025 08:05:00 PM
- CYCLACEL PHARMACEUTICALS HIGHLIGHTS PRECLINICAL DATA SHOWING THAT CANCER OF THE BILIARY TRACT IS SENSITIVE TO PLOGOSERTIB • GlobeNewswire Inc. • 08/04/2025 10:50:00 PM
- Cyclacel stock dips after trimming 270% surge amid volatility concerns • IH Market News • 07/16/2025 03:09:18 PM
- CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY • GlobeNewswire Inc. • 07/16/2025 01:00:00 PM
- Cyclacel Stock Surges 50% After Amending Exchange Agreement with FITTERS • IH Market News • 07/07/2025 01:34:48 PM
- CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER • GlobeNewswire Inc. • 07/07/2025 10:00:00 AM
- CYCLACEL PHARMACEUTICALS ANNOUNCES AMENDMENT TO EXCHANGE AGREEMENT • GlobeNewswire Inc. • 07/07/2025 10:00:00 AM
- Cyclacel Pharmaceuticals Announces Stock Split • GlobeNewswire Inc. • 07/02/2025 01:00:00 PM
- Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock • GlobeNewswire Inc. • 06/20/2025 08:30:00 PM
- CYCLACEL PHARMACEUTICALS REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT • GlobeNewswire Inc. • 06/03/2025 08:15:00 PM
